[HTML][HTML] Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: which role for conversion surgery? A systematic review and meta …
O De Simoni, M Scarpa, M Tonello, P Pilati, F Tolin… - Cancers, 2020 - mdpi.com
Simple Summary The development of new polychemotherapy regimens in patients with
metastatic pancreatic cancer (mPDAC) have demonstrated significant improvement in …
metastatic pancreatic cancer (mPDAC) have demonstrated significant improvement in …
[HTML][HTML] Oligometastasis in gastric cancer treatment: is there a place for the surgeon?
PP ASSUMPÇÃO, JMC SILVA, DQ Calcagno… - … Brasileiros de Cirurgia …, 2023 - SciELO Brasil
Metastatic gastric cancer traditionally hinders surgical treatment options, confining them to
palliative procedures. The presence of metastases in these tumors is classified as M1 …
palliative procedures. The presence of metastases in these tumors is classified as M1 …
Transcriptomic profiling identifies a risk stratification signature for predicting peritoneal recurrence and micrometastasis in gastric cancer
Purpose: Gastric cancer peritoneal carcinomatosis is fatal. Delay in detection of peritoneal
metastases contributes to high mortality, highlighting the need to develop biomarkers that …
metastases contributes to high mortality, highlighting the need to develop biomarkers that …
Dual drug-loaded PLGA fibrous scaffolds for effective treatment of breast cancer in situ
H Chen, J Wu, MSU Rahman, S Li, J Wang, S Li… - Biomaterials …, 2023 - Elsevier
Advanced metastatic breast cancer remains nearly an incurable disease. In situ therapy may
help patients with worse prognoses have better clinical outcomes by significantly reducing …
help patients with worse prognoses have better clinical outcomes by significantly reducing …
[HTML][HTML] Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal …
P Yu, Z Ye, G Dai, Y Zhang, L Huang, Y Du, X Cheng - BMC cancer, 2020 - Springer
Background There is no currently available treatment for peritoneal metastasis of gastric
cancer. This phase II study aimed to evaluate the efficacy and safety of neoadjuvant …
cancer. This phase II study aimed to evaluate the efficacy and safety of neoadjuvant …
[HTML][HTML] Role of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer
TY Xie, D Wu, S Li, ZY Qiu, QY Song… - World journal of …, 2020 - ncbi.nlm.nih.gov
BACKGROUND Gastric cancer is the second most common malignant tumor in China,
ranking third among all malignant tumor mortality rates. Hyperthermic intraperitoneal …
ranking third among all malignant tumor mortality rates. Hyperthermic intraperitoneal …
[HTML][HTML] Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone
RY Huang, HW Kou, PH Le, CJ Kuo, TH Chen… - Journal of Personalized …, 2022 - mdpi.com
The survival benefits of conversion surgery in patients with metastatic gastric cancer (mGC)
remain unclear. Thus, this study aimed to determine the outcomes of conversion surgery …
remain unclear. Thus, this study aimed to determine the outcomes of conversion surgery …
Treatment of gastric cancer patients during COVID-19 pandemic: the west is more vulnerable
WP Polkowski, K Sędłak… - Cancer Management …, 2020 - Taylor & Francis
The outbreak of the COVID-19 is currently the biggest international concern. Treatment of
gastric cancer (GC) patients in the pandemic era with high hospital burden and under …
gastric cancer (GC) patients in the pandemic era with high hospital burden and under …
Comparative analysis of postoperative complications after cytoreductive surgery and HIPEC in gastric cancer
F Merboth, S Garcia, J v. Renesse, M Distler… - Oncology Research …, 2022 - karger.com
Introduction: Patients with advanced gastric cancer (AGC) frequently show peritoneal
carcinomatosis (PC). PC reduces life expectancy and quality of life. Cytoreductive surgery …
carcinomatosis (PC). PC reduces life expectancy and quality of life. Cytoreductive surgery …
Management of Oligometastatic Disease in Esophagogastric Cancer: What Is the Evidence?
M Hingorani, H Stubley - Oncology Research and Treatment, 2023 - karger.com
Background: The concept of oligometastatic disease (OMD) was first introduced in 1995 by
Hellman and Weichselbaum and described as stage of transition between localized and …
Hellman and Weichselbaum and described as stage of transition between localized and …